From Concept to Commercialization: Developing a Drug-Device Combination Product
25 Aug 2026
Developing a drug-device combination product is not simply a matter of placing a medicinal product inside or alongside a medical device. It requires two traditionally different development disciplines to converge into one product that can consistently deliver the intended therapeutic outcome.
For pharmaceutical companies, this means that decisions about formulation, packaging, delivery, usability, manufacturing, and regulatory strategy can no longer be made independently. A change to one constituent part may affect the performance or quality of the complete product. This becomes important as combination products such as prefilled syringes, autoinjector, needle-safety systems, and other drug-delivery platforms become increasingly important for patient-centric treatment.
So, how should an organization approach the journey from an initial concept to commercial launch? A successful development program can be understood through several interconnected stages, beginning with the product concept and continuing through development, clinical use, manufacturing readiness, regulatory submission, and commercialization.
1. Define the Product Concept and Target Patient
The first stage is to establish what the combination product is intended to achieve and for whom it is being developed. The development team should understand the therapeutic need, intended patient population, route of administration, treatment environment, and expected user interaction with the product.
For example, a drug intended for self-administration may require a very different delivery strategy from a product administered by a trained healthcare professional. At this stage, the organization should establish the key characteristics of the intended product and consider the Target Product Profile (TPP) and, where applicable, the Quality Target Product Profile (QTPP).
These profiles help translate the intended therapeutic and quality objectives into development requirements. The important question is not only: What drug is being developed?
It is also: What delivery system will allow the drug to be used safely, effectively, and consistently by the intended population?
2. Establish the Drug-Device Strategy Early
Once the product concept is defined, the organization should determine the most appropriate device strategy.
Potential options may include:
- prefilled syringes;
- autoinjectors;
- needle-safety systems;
- pens;
- other established delivery platforms; or
- a newly developed device.
The choice between an established platform and a novel device can have significant consequences for the development program. An established platform may provide advantages because the technology and manufacturing approach are already understood. It may also reduce development uncertainty and potentially support a faster path toward commercialization.
However, an established device may not meet the needs of every patient population. For example, a therapy may require a specific delivery mechanism because of the formulation, dose, viscosity, administration requirements, or characteristics of the intended users. Therefore, the device strategy should be evaluated against the needs of the complete combination product rather than selected independently.
3. Build a Cross-Functional Development Team
Combination-product development requires collaboration between disciplines that may traditionally operate separately.
A development team may include:
- Pharmaceutical and CMC specialists: responsible for drug-product development and manufacturing considerations.
- Device and packaging engineers: responsible for delivery-system and packaging requirements.
- Quality professionals: responsible for quality controls and development processes.
- Regulatory specialists: responsible for understanding applicable regulatory requirements and submission strategy.
- Human factors specialists: responsible for usability and user interaction.
- Manufacturing specialists: responsible for process development, scalability, and production readiness.
Patient or user input can also be valuable, particularly when the product is intended for self-administration.
Why is this collaboration important? A formulation decision may influence device performance. A device decision may influence packaging. A packaging decision may influence stability. A usability finding may require a design modification. When these functions work independently, such interactions can be identified too late.
4. Evaluate Drug-Device Compatibility
Compatibility between the drug, its container, the delivery device, and packaging should be considered throughout development.
The combination product should be evaluated to determine whether the constituent parts can work together without negatively affecting safety, quality, stability, or performance.
Examples of relevant considerations can include:
- drug-product stability;
- material compatibility;
- container compatibility;
- device functionality;
- packaging design;
- storage conditions;
- delivery performance; and
- potential interactions between components.
For example, a device that performs adequately with one formulation may require additional evaluation when used with another formulation having different characteristics.
The development team therefore needs to consider not only whether the drug meets its requirements and whether the device meets its requirements, but whether the combination of the two remains suitable throughout the intended product lifecycle.
5. Integrate Human Factors and Usability
Human factors engineering is particularly important when the combination product will be used directly by patients or caregivers.
The evaluation should consider the complete user experience, including:
- packaging;
- instructions for use (IFU);
- preparation;
- device activation;
- administration;
- confirmation of successful use; and
- disposal.
Usability studies can identify potential use errors before the product reaches the market. For example, a patient may understand the medicine but have difficulty preparing or activating the delivery device. Alternatively, the device may function correctly from an engineering perspective but provide insufficient feedback to confirm that the dose has been delivered.
These issues should be identified early enough to allow design modifications. Human factors is therefore not simply a final usability check. It should contribute to product development from the early design stages.
6. Establish Risk Management and Design Controls
A robust risk-management approach should operate throughout development.
Potential risks can originate from the drug, the device, their interaction, the manufacturing process, or the way the product is used.
Examples include:
- device malfunction;
- incorrect dose delivery;
- drug-product instability;
- material interaction;
- packaging failure;
- user error; and
- manufacturing variability.
Design controls should provide a structured mechanism for translating user needs into requirements and subsequently demonstrating that the resulting product meets those requirements.
Risk-management outputs should also inform design decisions and testing strategies. The objective is to identify potential problems early, when they can still be addressed without creating major delays to the development program.
7. Develop and Test the Combination Product
The product should then progress through iterative development, testing, and refinement. This may involve prototype development, laboratory testing, usability studies, performance testing, and other verification and validation activities.
An iterative approach is particularly useful because information obtained during testing can be used to improve the product. For example, a usability study may identify a difficulty with device activation. A performance test may identify a delivery issue. A compatibility study may identify an interaction between a component material and the drug. Rather than treating these findings as isolated problems, the development team should evaluate their impact on the complete product and modify the design where necessary.
8. Prepare for Commercial Manufacturing
A product that performs successfully in development must eventually be manufactured consistently at commercial scale. This requires consideration of manufacturing processes from an early stage. For a combination product, manufacturing may involve multiple organizations and processes, including drug manufacturing, device manufacturing, assembly, labeling, and packaging.
Good manufacturing practices (GMP) and appropriate quality controls should be applied throughout these activities.Manufacturing processes should be demonstrated to be robust and scalable, with appropriate controls established to ensure that the final combination product maintains consistent quality and performance. The supply chain should also be considered. If a critical device component and the drug product are sourced through different supply chains, a disruption affecting either one can affect the availability of the complete product. The supply chain is therefore only as strong as its weakest critical link.
9. Make the Near-Commercialization Device Decision
As clinical development progresses, the organization may need to make final decisions about the drug-device strategy.
For example, a company may initially use a prefilled syringe during clinical development and later determine whether an autoinjector or needle-safety device would provide greater value for the intended patient population. These decisions should consider the TPP/QTPP, user needs, manufacturing capability, regulatory expectations, patient population, and commercial strategy.
The organization should also consider intellectual property where a novel device or delivery technology is being developed. A strong device strategy should therefore address not only technical performance, but also commercial viability and long-term product differentiation.
10. Prepare for Regulatory Submission and Commercial Launch
The final stages involve bringing together the evidence generated throughout development.
The regulatory submission should demonstrate that the combination product has been appropriately developed, evaluated, manufactured, and controlled according to the applicable requirements.
Documentation should provide evidence of:
- product requirements;
- design and development activities;
- risk management;
- compatibility;
- human factors;
- verification and validation;
- manufacturing controls; and
- quality requirements.
Once the product is approved, commercialization activities must ensure that manufacturing, supply, packaging, distribution, and quality systems are ready to support consistent market supply.
Partner with TS Quality & Engineering: Bridging Technical Complexity and Regulatory Excellence
The journey from concept to commercialization for a drug-device combination product involves much more than developing two components and bringing them together at the end.
Successful development requires early planning, cross-functional collaboration, iterative development, integrated risk management, human factors consideration, compatibility assessment, manufacturing readiness, and a carefully defined regulatory strategy.
The five principles are important:
- Collaborate early: Bring pharmaceutical, device, packaging, quality, regulatory, manufacturing, and human-factors expertise together from the beginning.
- Manage risk proactively: Identify technical, usability, compatibility, manufacturing, and regulatory risks before they become major obstacles.
- Develop iteratively: Use testing, user feedback, and development findings to continuously improve the product.
- Maintain regulatory control: Ensure that drug, device, packaging, quality, and documentation requirements are addressed throughout development.
- Plan for commercialization: Consider manufacturability, supply-chain resilience, intellectual property, scalability, and the final device strategy before the product reaches the market.
Ultimately, the successful commercialization of a combination product depends on treating the drug and device as parts of one integrated therapeutic solution.
The objective is not simply to develop a drug that works and a device that works.
The objective is to bring together a drug, delivery system, user experience, manufacturing process, and quality system that can work together consistently to deliver the intended benefit to patients.
Navigating the complex convergence of pharmaceuticals and medical devices requires more than just technical execution—it demands a unified regulatory, quality, and engineering strategy. At TS Quality & Engineering, we specialize in bridging these two distinct worlds, turning intricate drug-device development challenges into streamlined, compliant, and commercially viable realities. Whether you need end-to-end design control integration, robust human factors engineering, or proactive risk management across your product lifecycle, our cross-functional experts ensure your innovation delivers safe, effective, and consistent therapeutic outcomes to market without friction. Partner with TS Quality & Engineering to accelerate your journey from initial concept to successful commercial launch.
